Product Pipeline

EffRx created Binosto® by taking this product from start to finish, including benefit assessment, formulation development, clinical development, FDA approval through a 505(b)(2) route, licensing to and launch via commercial partners. The approval and commercial launch of Binosto® provides EffRx with an important proof-of-concept and highlights a number of potential benefits of EffRx‘ technology.

Our lead development product, EX404, targets PolyCystic Ovarian Syndrome (PCOS) in adolescents and adults. EffRx received an orphan drug designation (ODD) from FDA for the adolescent PCOS in May 2014.

Product / Project Indication Development Phase
Binosto®
(buffered effervescent alendronate)
Osteoporosis Commercialized in multiple markets
EX404 (USA) Adolescent PCOS (orphan)
Adult PCOS
IND with FDA
Phase I